Notice of Half-Year Financial Results
Faron Pharmaceuticals Ltd. announced that it will publish its unaudited half-year financial results for the six months ended June 30, 2026, on Wednesday, August 26, 2026. The company will host a virtual briefing and Q&A session for investors, analysts, and media on the same day, featuring the Chief Executive Officer and Chief Financial Officer. The half-year report, presentation, and webcast replay will be made available on the company's website following the event.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | August 19, 2026 at 09:00:00 EEST |
Faron Pharmaceuticals will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026
TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report its unaudited half-year financial results for the six months ended 30 June 2026, on Wednesday, 26 August 2026.
A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer and Jurriaan Dekkers, Chief Financial Officer at 08:00 am (EDT) / 1:00 pm (BST) / 3:00 pm (EEST) on Wednesday, 26 August 2026. Webcast registration link: Faron 2026 Half-Year Financial Results
The half-year report, presentation, and a replay of the webcast will be published afterward on the Company’s website at: Reports and presentations – Faron
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.